Over the last seven decades, a significant scientific contribution took place in the delineation
of the implications of vascular endothelial‐derived growth factor (VEGF) in the processes of …

Retinopathy of prematurity (ROP) is a significant cause of potentially preventable blindness
in preterm infants worldwide. It is a disease caused by abnormal retinal vascularization that …

Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …

The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

Topic To compare bevacizumab, ranibizumab, aflibercept, and laser treatment as primary
therapies for retinopathy of prematurity (ROP) in terms of retreatment rate. Clinical relevance …

The population of infants at risk for retinopathy of prematurity (ROP) varies by world region;
in countries with well developed neonatal intensive care services, the highest risk infants are …

Importance Anti–vascular endothelial growth factor (VEGF) therapies are a novel treatment
option in retinopathy of prematurity (ROP). Data on dosing, efficacy, and safety are …

Purpose To compare structural outcome at age 4 years of eyes treated with intravitreal
injection of bevacizumab with fellow eyes treated with conventional laser photoablation in …

Purpose Intravitreal bevacizumab is increasingly used to treat severe retinopathy of
prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter …

Importance One of the biggest challenges when using anti–vascular endothelial growth
factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long …